MarketFriction

Lyka Labs Ltd

NSE LYKALABS · BSE 500259 · Pharmaceuticals
₹81.55 -1.99%
NSE close2026-10-01
52 week range44.10 - 100.94
Market cap₹298 Cr.
ESM Price band 5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales27.9932.5627.7730.1141.1633.8033.4333.0336.6630.7328.0342.31
Expenses23.8225.6925.7526.4036.2128.6129.3529.3539.2029.0834.4837.76
Operating Profit4.176.872.023.714.955.194.083.68-2.541.65-6.454.55
OPM %14.90%21.10%7.27%12.32%12.03%15.36%12.20%11.14%-6.93%5.37%-23.01%10.75%
Other Income-0.180.540.320.560.030.830.820.631.091.160.610.42
Interest1.191.281.070.650.540.610.470.850.790.820.701.01
Depreciation3.592.842.901.761.761.831.422.112.152.152.042.01
Profit before tax-0.793.29-1.631.862.683.583.011.35-4.39-0.16-8.581.95
Tax %-22.78%38.60%28.22%30.65%28.36%24.30%32.89%26.67%-26.65%-6.25%-6.06%-5.13%
Net Profit-0.491.78-2.091.291.912.702.030.99-3.22-0.15-8.072.05
EPS in Rs-0.150.54-0.630.400.590.760.500.26-0.940.00-2.130.57
Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1301106071618619493111138128138
Expenses1108763736567937695121132141
Operating Profit2023-4-2-420101171618-3-3
OPM %16%21%-6%-2.7%-6%23%52%18%14%13%-2.7%-2.0%
Other Income8-241-300-4-41243
Interest1519107202620125233
Depreciation91011788171413788
Profit before tax4-8-20-15-62-1459-13-111-12-11
Tax %-5%-19%-5%-59%1%-29%35%-0%182%29%-11%
Net Profit4-7-19-6-63-1038-13-38-10-9
EPS in Rs1.67-2.51-6.14-1.97-21.10-4.0313.59-4.30-0.752.24-2.81-2.50
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth0%8%11%-3%
Compounded Profit Growth%1%-32%-219%
Stock Price CAGR2%2%-11%-14%
Return on Equity%%-2%-10%
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital222222282829292931333636
Reserves2022162115-43-54-1515356957
Borrowings1371211261139614116313075593949
Other Liabilities1007788677673524231303233
Total Liabilities279242252229216200190186152157176175
Fixed Assets122104133116108105989468588587
CWIP2730242831282618162312
Investments000000000000
Other Assets13010794857768667467769086
Total Assets279242252229216200190186152157176175
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity271231112759799225
Cash from Investing Activity3717-13-3-4-0-0-67-9-12-9
Cash from Financing Activity-60-30-19-10-233-12-63-22254
Net Cash Flow4-1-0-3-19-310-5-6-50
Free Cash Flow552818723487215-7-10-6
CFO/OP97%60%143%-318%-1,462%-131%49%79%52%21%28%-159%
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days12412197125754837357989114100
Inventory Days7756901396569415668788299
Days Payable22021826630121619214196919898122
Cash Conversion Cycle-18-41-79-37-75-76-63-555689776
Working Capital Days-220-242-357-735-265-242-118-121-0235123
ROCE %10%7%9%-8%-5%-6%10%61%5%4%10%-6%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.81%54.81%54.81%58.11%58.11%58.11%58.16%58.16%58.16%58.16%58.16%58.45%
FIIs0.18%0.17%0.17%0.15%0.15%0.15%0.24%0.16%0.17%0.17%0.29%0.17%
DIIs0.41%0.62%0.81%0.75%0.66%0.66%0.66%0.66%0.66%0.66%0.66%0.66%
Public44.61%44.41%44.21%40.99%41.08%41.07%40.93%41.02%40.99%40.99%40.89%40.73%
No. of Shareholders26,65226,42225,71725,71628,94329,09928,47228,18927,74327,15526,72729,369

Fundamentals

Market Cap₹ 298 Cr.
Current Price₹ 82.5
Book Value₹ 25.9
ROCE-5.98 %
ROE-10.2 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-3%
Compounded Profit Growth (TTM)-219%
Consolidated figures.
Valuation
Market capRs 291 Cr
Enterprise valueRs 339 Cr
Price to book3.15x
Price to sales2.11x
EV / EBITDA690.94x
EV / sales2.46x
Price to cash flow55.54x
Earnings yield-3.45%
P/E, 3-year average44.74x
P/B, 3-year average3.44x
P/E, 5-year average27.35x
P/B, 5-year average9.30x
Profitability
Operating margin (excl. other income)-2.72%
Operating margin (incl. other income)0.01%
EBITDA margin0.36%
Pre-tax margin-8.12%
Net profit margin-7.28%
Net margin, latest quarter4.89%
ROE-10.18%
ROCE-5.92%
ROA-5.72%
ROE, 3-year average-1.76%
ROCE, 3-year average2.39%
ROA, 3-year average-0.84%
ROE, 5-year average-135.25%
ROCE, 5-year average12.52%
ROA, 5-year average2.08%
ROIC (approx.)-4.98%
Tax rate11.38%
Other income / net worth3.79%
Growth
Sales growth (latest year)-7.26%
Profit growth (latest year)-225.22%
Sales CAGR, 3 years11.33%
Sales CAGR, 5 years8.29%
Sales growth QoQ50.95%
Sales growth YoY (latest quarter)28.10%
Profit growth YoY (latest quarter)122.58%
Per share
EPS (TTM)Rs -2.81
EPS (latest year)Rs -2.81
EPS (latest quarter)Rs 0.58
EPS, 3-year averageRs -0.44
EPS, 5-year averageRs 1.59
Book value per shareRs 25.89
Sales per shareRs 38.59
Cash flow per shareRs 1.47
Free cash flow per shareRs -1.68
Efficiency
Asset turnover0.74x
Fixed asset turnover1.47x
Inventory turnover4.36x
Inventory days84 days
Debtor days100 days
Debtors turnover3.67x
Creditor days122 days
Cash conversion cycle76 days
Working capital days23 days
Leverage
Total debtRs 49 Cr
Cash and bankRs 1 Cr
Net debtRs 48 Cr
Debt to equity0.53x
Net debt / EBITDA96.96x
Interest coverage-2.37x
Owners' fund to total sources52.93%
Debt to assets28.00%
Cash flow
Cash from Operating Activity (latest year)Rs 5 Cr
Cash from Investing Activity (latest year)Rs -9 Cr
Cash from Financing Activity (latest year)Rs 4 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -6 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years4.85x
Sales to cash flow24.51x
Statement figures
Net sales (TTM)Rs 138 Cr
Net sales (latest year)Rs 128 Cr
Sales (latest quarter)Rs 42 Cr
Operating profit excl. other income (latest year)Rs -3 Cr
Operating profit (latest quarter)Rs 5 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs -3 Cr
Profit before tax (TTM)Rs -11 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs -10 Cr
Net profit (latest year)Rs -10 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 8 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 59 Cr
Total expenditure (latest year)Rs 132 Cr
Total income (latest year)Rs 132 Cr
Share capitalRs 36 Cr
ReservesRs 57 Cr
Shareholders' fundsRs 92 Cr
Total assetsRs 175 Cr
Net blockRs 87 Cr
Capital work in progressRs 2 Cr
InvestmentsRs 0 Cr
ReceivablesRs 35 Cr
InventoryRs 14 Cr
Other liabilitiesRs 33 Cr
Shares outstanding (crore)3.57
Ownership
Promoter holding58.45% (+0.29 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 3.15 is at the 38th percentile (median 4.52).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodLYKALABSNifty 50Difference
1 week-6.3%-2.8% -3.5 pts
1 month+10.4%-6.8% +17.2 pts
3 months+14.2%-7.6% +21.8 pts
6 months+81.4%+0.4% +81.0 pts
1 year-15.1%-9.9% -5.2 pts
2 years-45.7%-13.6% -32.2 pts
3 years-29.4%+14.2% -43.6 pts
5 years+6.2%+27.9% -21.7 pts

Red flags

F-score 3 of 8
lookOn NSE surveillance On NSE surveillance: ESM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹42 Cr +28.1% vs Jun 2025. Net profit ₹2 Cr +107.1%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-08-01Annual General Meeting
2023-07-21Annual General Meeting
2022-07-21Annual General Meeting
2021-07-22 Annual General Meeting
2020-09-16 Annual General Meeting
2019-09-06 Annual General Meeting
2018-09-19 Annual General Meeting
2017-09-21 Annual General Meeting
2016-09-19 Annual General Meeting
2015-12-22 Annual General Meeting
2014-12-22Annual General Meeting
2013-09-19Annual General Meeting
2012-09-26Annual General Meeting
2011-04-20Annual General Meeting
2010-03-22Annual General Meeting
2008-10-07Annual General Meeting
2007-08-16Agm Bc Start Date Revised
2006-05-04Agm
DateTypeWhat it says
2026-08-11Shareholder meetingVoting results.
2026-08-11General UpdatesGeneral Updates
2026-08-10Shareholder meetingProceedings of Annual General Meeting held on August 10, 2026
2026-08-10General UpdatesGeneral Updates
2026-08-10Board meeting outcomeLyka Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-17General UpdatesGeneral Updates
2026-07-17General UpdatesGeneral Updates
2026-07-17Shareholder meetingNotice of Annual General Meeting to be held on August 10, 2026
2026-06-30General UpdatesGeneral Updates
2026-06-26General UpdatesGeneral Updates
2026-06-17General UpdatesGeneral Updates
2026-06-12General UpdatesGeneral Updates
2026-06-11General UpdatesGeneral Updates
2026-06-11Price movementSignificant movement in price has been observed in Lyka Labs Limited. The Exchange, in order to ensure that investors have latest relevant information...
2026-06-04General UpdatesGeneral Updates
2026-05-25Board meeting outcomeLyka Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-30Credit RatingCredit Rating
2026-04-10Disclosure under SEBI TakeovLyka Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial...
2026-04-09Disclosure under SEBI TakeovIpca Laboratories Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substa...
2026-04-09General UpdatesGeneral Updates
2026-04-09Price movementSignificant movement in price has been observed in Lyka Labs Limited. The Exchange, in order to ensure that investors have latest relevant information...
2026-04-08Price movementSignificant movement in price has been observed in Lyka Labs Limited. The Exchange, in order to ensure that investors have latest relevant information...
2026-03-31Board meeting outcomeOutcome of Board Meeting held on March 31, 2026.
2026-03-17General UpdatesGeneral Updates
2026-03-06ResignationResignation of Rajaram Madhav Walavalkar & Co., Cost Accountant as Other of the company w.e.f. March 05, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-09-29NCLTLyka Labs Ltd Vs
2020-08-07NCLTLyka Labs Ltd Vs
2020-07-27NCLTLyka Labs Ltd Vs
2020-07-22NCLTLyka Labs Ltd Vs
2020-06-04NCLTLyka Labs Ltd Vs
2020-03-04NCLATLyka Labs Ltd. VS Modi Lifecare Industries Ltd.
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
EPS in the scrip is zero (4 trailing quarters)ESM: stage 1Less than 100 unique PAN traded in previous 30 days
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03